Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapy products derived from its proprietary allogeneic gamma delta T cell platform. Founded in 2013 and headquartered in Motherwell, United Kingdom, the company focuses on advancing cell-based therapies for serious medical conditions. Its product pipeline includes OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy currently in phase 2/3 clinical trials targeting acute myeloid leukemia, and ImmuniStim, an unmodified cell therapy designed to treat viral infections and various cancers. TC BioPharm emphasizes the development of safer, cost-effective CAR-T cell therapies with the potential to address multiple cancer types and improve patient health outcomes. Operating within the biotechnology sector, TC BioPharm leverages its integrated preclinical to clinical development model to innovate in cancer and infectious disease treatment, contributing to advancements in cell therapy and immunotherapy research.
£0.01
+£0.00 (+0.00%)
Price from 8 days ago
Negative free cash flow of -£13M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£12M
▼ -105.8% YoY
Op. Margin
—
ROIC
-224.26%
▲ +71.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£13M
▼ -17.7% YoY
Op. Cash Flow (TTM)
-£10M
▼ -191.6% YoY
Net Debt
£284K
Cash & Equiv.
£1M
Continue Research
TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, TC BioPharm (Holdings) plc American Depositary Receipt scores 0/100 on Intrinsiqq's , weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
TC BioPharm (Holdings) plc American Depositary Receipt scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -224.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh TCBPY's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.